Document Detail

Unmet needs in modern vaccinology: adjuvants to improve the immune response.
MedLine Citation:
PMID:  20713254     Owner:  NLM     Status:  MEDLINE    
The key objective of vaccination is the induction of an effective pathogen-specific immune response that leads to protection against infection and/or disease caused by that pathogen, and that may ultimately result in its eradication from humanity. The concept that the immune response to pathogen antigens can be improved by the addition of certain compounds into the vaccine formulation was demonstrated about one hundred years ago when aluminium salts were introduced. New vaccine technology has led to vaccines containing highly purified antigens with improved tolerability and safety profiles, but the immune response they induce is suboptimal without the help of adjuvants. In parallel, the development of effective vaccines has been facing more and more important challenges linked to complicated pathogens (e.g. malaria, TB, HIV, etc.) and/or to subjects with conditions that jeopardize the induction or persistence of a protective immune response. A greater understanding of innate and adaptive immunity and their close interaction at the molecular level is yielding insights into the possibility of selectively stimulating immunological pathways to obtain the desired immune response. The better understanding of the mechanism of 'immunogenicity' and 'adjuvanticity' has prompted the research of new vaccine design based on new technologies, such as naked DNA or live vector vaccines and the new adjuvant approaches. Adjuvants can be used to enhance the magnitude and affect the type of the antigen-specific immune response, and the combination of antigens with more than one adjuvant, the so called adjuvant system approach, has been shown to allow the development of vaccines with the ability to generate effective immune responses adapted to both the pathogen and the target population. This review focuses on the adjuvants and adjuvant systems currently in use in vaccines, future applications, and the remaining challenges the field is facing.
Geert Leroux-Roels
Related Documents :
20826614 - The th1 immune response to plasmodium falciparum circumsporozoite protein is boosted by...
18706954 - Exercise enhances vaccine-induced antigen-specific t cell responses.
7668034 - Dependence of ricin toxoid vaccine efficacy on the structure of poly(lactide-co-glycoli...
15734064 - Comparative immunomodulatory properties of a chitosan-mdp adjuvant combination followin...
21099444 - Effectiveness of haemophilus influenzae type b conjugate vaccine for prevention of meni...
24990904 - Immunogenicity of the trivalent inactivated influenza vaccine in young children less th...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Vaccine     Volume:  28 Suppl 3     ISSN:  1873-2518     ISO Abbreviation:  Vaccine     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-17     Completed Date:  2010-11-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8406899     Medline TA:  Vaccine     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  C25-36     Citation Subset:  IM    
Copyright Information:
2010 Elsevier Ltd. All rights reserved.
Centre for Vaccinology, Ghent University and Hospital, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adaptive Immunity
Adjuvants, Immunologic / pharmacology*
Immunity, Innate
Vaccines / immunology*
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Vaccines

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Key concepts in immunology.
Next Document:  Seasonal influenza vaccinations: specialized products for different target groups.